NCT06615752 - Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

February 28, 2029

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

DRUG

green tea and quercetin + docetaxel

green tea and quercetin supplements in combination with docetaxel infusion

DRUG

Placebo + docetaxel

Placebo will be given along with docetaxel chemotherapy

Trial Locations (1)

RECRUITING

Charles R. Drew University of Medicine and Science, Los Angeles

All Listed Sponsors

collaborator

National Institute on Minority Health and Health Disparities (NIMHD)

NIH

collaborator

Watts Healthcare Corporation

UNKNOWN

lead

Charles Drew University of Medicine and Science

OTHER